Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With SAGE-217 in Adult Subjects With Major Depressive Disorder

NCT03864614 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT03864614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03864614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With SAGE-217 in Adult Subjects With Major Depressive Disorder
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Completed
Start date
February 27, 2019
Completion date
June 22, 2023
Enrollment
1,515 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder